Top of this page
Skip navigation, go straight to the content

Our Science Dapirolizumab pegol

Clinical Study Information - Dapirolizumab pegol

Disease area
Abbreviated title Phase Study ID Registry database Study results Lay summary Publication (if available)
Systemic Lupus Erythematosus A Phase 2b, randomized, double-blind, PBO-controlled, parallel-group, dose-ranging study followed by an observational period that will evaluate the efficacy of Dapirolizumab Pegol (DZP) in inducing disease control and the safety of DZP in subjects with moderately to severely active Systemic Lupus Erythematosus (SLE) who are receiving standard-of-care medications. Phase 2 SL0023